Citations

Clear

390 citation(s) found for "Loftus, E".

STEM-15. STAT5-OLIG2 TRANSCRIPTIONAL COMPLEX MEDIATES GLIOMA STEM CELL SELF RENEWAL AND INVASION
Miller, Aunay , Cascio, Costanza Lo , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Dufault, Matthew , Sereduk, Christopher, Loftus, Joseph C. , Mehta, Shwetal , Orndorff, Keely, Sereduk, Chris , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v35-v36

10.1093/neuonc/noad179.0140 Get It

Abstract Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, despite current treatment options. One of the major contributing factors to this dismal outcome is a subset of cells called glioma stem cells (GSCs) that are highly tumorigenic, invasive, and resistant to conventional treatments. Thus, studies that focus on the properties of GSC biology are needed to develop novel therapies to improve overall survival. Here we report a novel role of STAT5 in GSC stemness and survival. In GBM tumors, STAT5 has been shown to be active in the infiltrative, residual population of cells remaining post-surgery. Knockdown of STAT5 results in the decrease in GSC stemness and therapeutic resistance. Interestingly, we find that expression of OLIG2, a key cell fate factor important for the tumorigenic potential of GSCs, affects STAT5 activation with a positive correlation between OLIG2 and STAT5 mRNA expression in GBM tumors. Furthermore, we find that in GSCs expressing EGFRvIII, STAT5 interacts with OLIG2 and pharmacological inhibition of STAT5 activation or knockdown of STAT5 expression results in decrease of OLIG2-mediated GSC invasion. Together, these data suggest a novel transcriptional complex, STAT5-OLIG2, in the potential role for GSC survival, maintenance, and invasion.
STEM-20. REGULATION OF GLIOMA STEM CELL MAINTENANCE AND THERAPEUTIC RESISTANCE BY EGFR MISSENSE MUTATIONS
Weaver, Sidney , Miller, Aunay , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Kloss, Jean , Sereduk, Christopher, Loftus, Joseph C. , Mehta, Shwetal , Sereduk, Chris , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v37-v37

10.1093/neuonc/noad179.0145 Get It

Abstract Glioblastoma (GBM) tumors contain a subpopulation of glioma stem cells (GSC) which can escape therapeutic effects through self-renewal and invasion. Epidermal growth factor receptor (EGFR) mutations are the most common alteration in GBM. EGFRvIII (deletion of exons 2-7) is observed in GBM (20-25%) resulting in a constitutively activated EGFR receptor. In addition, extracellular domain missense point mutations, (e.g. G598V, A289V, R108K) are observed in GBM (14.4%). These missense mutations in the EGFR extracellular domain also induces a highly active receptor by enhancing ligand binding. Earlier reports have shown that these EGFR missense point mutations have exhibited therapeutic resistance; however, the molecular mechanism of these missense point mutations in GBM remains unknown. Previous studies in our lab showed that EGFRvIII promotes GSC maintenance and therapeutic resistance via oligodendrocyte transcription factor 2 (OLIG2) signaling. OLIG2 is universally expressed in glioma and essential for reprogramming GBM cells into stem-like tumor cells. Increased OLIG2 expression promotes invasion, growth, proliferation, and survival. Here we report an increase in OLIG2 protein expression in GSCs harboring EGFR-G598V or EGFR-A289V mutations, suggesting these mutations may support stemness properties in GBM tumors. GSC expressing these point mutations display increased self-renewal, growth, and survival. In addition, EGFR-G598V and EGFR-A289V trigger distinct downstream signaling pathways in GSCs to regulate OLIG2 function. Hence, we hypothesize that GBM tumors harboring EGFR missense mutations (G598V, A289V) influence stem cell properties via multiple pathways to evade therapeutic effects and inhibiting these different signaling pathways will decrease therapeutic resistance in GBM. Understanding the mechanism of these EGFR mutations may lead to improved therapeutic strategies for GBM patients.
ANGI-05. CDKN2A/B HOMOZYGOUS DELETION IN IDH-MUTANT ASTROCYTOMA ALTERS TUMOR CELL INVASION AND VASCULAR FORMATION
Grief, Dustin, Sereduk, Christopher, Hu, Leland , Loftus, Joseph C. , D’Angelo, Fulvio , Caruso, Francesca Pia , Sereduk, Chris , Ceccarelli, Michele , Tran, Nhan L. , Ensign, Shannon P. Fortin

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v2-v2

10.1093/neuonc/noad179.0005 Get It

Abstract High-grade gliomas represent the most common type of primary adult malignant brain tumor historically diagnosed and graded from histologic criteria alone. Gliomas harboring isocitrate dehydrogenase (IDH) 1 or 2 mutations are associated with lower grade tumors and portend a favorable prognosis relative to IDH-wildtype glioma. However, molecular profiling has identified additional alterations in lower grade gliomas that confer an aggressive high-grade phenotype and a worse clinical prognosis. Of these, the loss of CDKN2A/B in IDH-mutant astrocytoma is the strongest implicated alteration and is sufficient to define a grade 4 tumor regardless of histologic grade. However, there remain no effective therapies targeted at molecular subgroups in aggressive gliomas to date. Here, we sought to elucidate the biologic pathways and functional outcomes associated with the acquisition of high-grade behavior under loss of CDKN2A/B in IDH-mutant astrocytoma to inform future therapeutic strategies. We analyzed a cohort of patient IDH-mutant astrocytomas with whole exome and RNA sequencing data and found several candidate genes/pathways regulated concurrent with CDKN2A/B loss, including regulators of embryonic development, extracellular matrix organization and regulation of vascular processes. Moreover, we identified 1 tumor that displayed intratumoral heterogeneity of CDKN2A/B expression across biopsies. Using grade 4 IDH-mutant astrocytoma patient-derived (PDX) and established cell-lines harboring CDKN2A/B homozygous deletion, we then stably re-expressed cell cycle regulators p14, p15, and p16 using a Tet-inducible lentiviral system and confirmed their decreased proliferation as compared to parental lines. IDH-mutant cell lines with re-expression of p14, p15 or p16 were characterized by differential transcription factor activation and distinct vascular formation patterns as compared to parental lines. These lines also displayed an increased cell migration and invasive potential and were associated with enhanced integrin signaling through integrin beta-3. Together, our work supports a hypothesis of regional tumor evolution with distinct biologic phenotypes across IDH-mutant gliomas.
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme
Raine, Tim , Ishiguro, Yoh , Rubin, David T. , Finney‐Hayward, Tricia , Vladea, Ramona, Liu, John , Phillips, Charles M., Cheng, Erica, Loftus, Edward V. , Targownik, Laura , Loftus, Edward V , Rubin, David T , Raine, Tim , Targownik, Laura E.

Mayo Clinic

Journal of Crohn's and Colitis | November 9, 2023 | Volume: 18 | Issue: 5 | Pages: 695-707

10.1093/ecco-jcc/jjad190 | PMID 37942921 Get It

Abstract Background and Aims This post hoc analysis assessed the efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis stratified by corticosteroid use from the ulcerative colitis Phase 3 clinical trial programme. Methods Patients were randomised [1:2] to 8 weeks’ placebo or upadacitinib 45 mg once daily; Week 8 responders were re-randomised [1:1:1] to 52 weeks’ placebo or upadacitinib 15 or 30 mg daily. Corticosteroid dose was kept stable during induction but tapered according to a protocol-defined schedule [or investigator discretion] during maintenance Weeks 0–8. Efficacy outcomes and exposure-adjusted, treatment-emergent adverse event [TEAE] rates were assessed for induction and maintenance stratified by corticosteroid use at induction baseline. Results Overall, 377/988 [38%] patients were receiving corticosteroids at induction baseline [placebo, n = 133; upadacitinib 45 mg, n = 244] and 252 [37%] of the 681 clinical responders who entered maintenance were on corticosteroids at induction baseline [n = 84 for each treatment]. Similar proportions of patients receiving upadacitinib achieved clinical remission per Adapted Mayo Score with and without baseline corticosteroids at Weeks 8 and 52. The total proportion of patients re-initiating corticosteroids was higher with placebo [24/84;29%] vs upadacitinib 15 mg [16/81; 20%)] and 30 mg [11/81; 14%]. During induction, patients receiving corticosteroids at baseline had higher rates of TEAEs, serious TEAEs, and serious infections vs those not receiving corticosteroids; however, TEAE rates were similar during maintenance after corticosteroid withdrawal. Conclusions Upadacitinib is an effective steroid-sparing treatment in patients with moderately to severely active ulcerative colitis. Clinicaltrials.gov identifiers: NCT02819635; NCT03653026
S1160 Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately-to-Severely Active Crohn’s Disease
Dubinsky, Marla C. , D’Haens, Geert , Lacerda, Ana P. , Dubcenco, Elena, Anyanwu, Samuel I., Garrison, Andrew, Dewit, Olivier , Juillerat, Pascal , Panaccione, Remo , Fujii, Toshimitsu , Anyanwu, Samuel, Doshi, Chirag, Liu, Jianzhong , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S887-S888

10.14309/01.ajg.0000954280.83972.54 Get It

S1187 Fecal Microbiota Transplantation and Clinical Outcomes Among Inflammatory Bowel Disease Patients: An Umbrella Review
Malik, Sheza , Naqvi, Syed Arsalan Ahmed , Loftus, William F., Renisha, Redij, Khanna, Sahil , Loftus, William, Renisha, Redij, Tariq, Raseen

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S907-S907

10.14309/01.ajg.0000954388.76188.f5 Get It

S1166 Time to Relapse During Upadacitinib Maintenance Therapy in Patients With Ulcerative Colitis Who Had a Clinical Response to Induction Therapy
Dubinsky, Marla C. , Kujawski, Michelle, Eccleston, Jason , Yao, Xuan , Axelrad, Jordan E. , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S892-S893

10.14309/01.ajg.0000954304.38542.d7 Get It

S976 Contemporary Sociodemographic and Regional Differences Among Hospitalized Patients With Inflammatory Bowel Diseases in the United States
Pemmasani, Gayatri , Tremaine, William J., Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S736-S737

10.14309/01.ajg.0000953544.06582.08 Get It

S971 Risk of Major Adverse Cardiovascular Events in Patients With Inflammatory Bowel Diseases or Other Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: A Systematic Review and Network Meta-Analysis
Mattay, Shivani, Saturno, Dany, Ciorba, Matthew A. , Yarur, Andrés , Singh, Siddharth , Yarur, Andres J , Zamani, Mohammad , Loftus, Edward V. , Deepak, Parakkal

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S731-S732

10.14309/01.ajg.0000953524.09735.b1 Get It

S909 Efficacy of Upadacitinib in Patients With Crohn’s Disease Activity Index-Based Eligibility Criteria: Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Lichtenstein, Gary R. , DuVall, Aaron, Chapman, J. Casey, Lacerda, Ana P. , Anyanwu, Samuel I., Garrison, Andrew, Dubinsky, Marla C. , Rubin, David T. , Loftus, Edward V. , Regueiro, Miguel , Anyanwu, Samuel, O’Brien, Daniel J. , Liu, Jianzhong

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S678-S679

10.14309/01.ajg.0000953276.85317.47 Get It